bioAffinity Technologies, Inc. filed a Form S-1 registration statement with the U.S. Securities and Exchange Commission on November 20, 2026, to register up to 999,673 shares of common stock for resale by selling stockholders.

Key Highlights

  • Shares registered: Up to 999,673 shares of common stock, par value $0.007 per share, are being registered for resale by selling stockholders.
  • Warrant breakdown: The shares consist of 980,072 shares issuable upon exercise of Series C warrants (Private Placement Warrants) and 19,601 shares issuable upon exercise of Placement Agent Warrants.
  • Source agreement: The Private Placement Warrants were issued pursuant to a securities purchase agreement dated October 8, 2026, between the company and one selling stockholder.
  • Placement agent: The Placement Agent Warrants were issued to WallachBeth Capital LLC under a placement agency agreement also dated October 8, 2026.
  • No proceeds to company from resale: The company disclosed it will not receive any proceeds from the sale of shares by the selling stockholders, though it may receive cash from any cash exercise of the Warrants.
  • Last reported share price: On November 19, 2026, the last reported sale price of the common stock was $1.85 per share.
  • Filer classification: The registrant identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company.

bioAffinity Technologies Registers Warrant-Backed Shares From October 2026 Private Placement

bioAffinity Technologies, Inc. (NASDAQ:BIAF), a Delaware corporation headquartered at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217, filed a Form S-1 registration statement on November 20, 2026. According to the filing, the registration covers up to 999,673 shares of common stock that selling stockholders may offer and resell from time to time. The company's Chief Executive Officer is Maria Zannes, and legal counsel for the registrant includes Richard A. Friedman, Esq. and Sean F. Reid, Esq. of Sheppard, Mullin, Richter and Hampton LLP.

The filing disclosed that the 999,673 shares are comprised of two components: 980,072 shares issuable upon exercise of Series C warrants issued under a securities purchase agreement entered into on October 8, 2026, and 19,601 shares issuable upon exercise of warrants issued to placement agent WallachBeth Capital LLC under a placement agency agreement of the same date. The registration statement was filed under Rule 415, permitting offerings on a delayed or continuous basis. The company stated it will bear the expenses of registering the shares, while selling stockholders will bear any commissions or discounts attributable to their sales.

The prospectus noted that the registration of these shares does not necessarily mean the selling stockholders will offer or sell any shares under this registration statement or at any time in the near future. The filing contains forward-looking statements, which the prospectus characterizes as subject to its cautionary language. The registration statement had not yet become effective as of the filing date, and the prospectus was described as preliminary and subject to completion.

What Was Disclosed

bioAffinity Technologies filed an S-1 registration statement on November 20, 2026, to register 999,673 shares of common stock for resale by selling stockholders, consisting of shares underlying Series C and placement agent warrants issued in connection with an October 8, 2026 transaction.